Introduced as an antibody-drug conjugate, the Adcetris 50 mg is recommended for treating patients with relapsed or refractory Hodgkin lymphoma and patients with anaplastic large cell lymphoma. The adcetris 50 mg injection should be administered under the close supervision of a doctor experienced in the use of anti-cancer agents. The standard dose of adcetris should be given by a healthcare professional as an intravenous (IV) infusion.